Based on the current week's news, the sentiment is positive for Cipla shares. There are two notable events:

1. Nomura recommends a "Buy" rating for Cipla with a target price of Rs 1,780, indicating a potential upside for the stock.
2. The US approval for a key cancer drug has made Cipla shares an attractive buy, despite tariff concerns, suggesting that the company's growth potential is not hindered by external factors.

The tone of the news is positive, as both articles convey a sense of optimism about Cipla's prospects. The first article explicitly recommends a "Buy" rating, while the second article highlights the company's growth potential despite challenges. Overall, the news sentiment is bullish, which could lead to a potential increase in the stock price.